On September 30, the FDA removed tirzepatide from the shortage list, creating confusion for patients and providers who rely on compounding pharmacies.
Vickie Paesano, third-generation owner of Preston’s Pharmacy, a trusted pharmacy serving 27 states, shares insights as both a pharmacist and the owner of Core Aesthetic, her med spa.
Bill and Vickie discuss:
- What some pharma reps are doing on the ground to circumvent the provider relationship and block compounded versions of tirzepatide
- How the latest FDA regulations are impacting compounding pharmacies and aesthetic practices
- Vickie’s thoughts on navigating changing regulations from both sides of the industry
- Vickie’s predictions on how this tug-of-war over compounding will play out
LinksRead the
FDA’s latest update to compounding pharmacies
Learn more about
Core AestheticAbout Aesthetic AppealAesthetic Appeal is where Aesthetic Brokers brings you the latest insights straight from Southern California. We break down what’s happening in the medical aesthetics world—especially when it comes to private equity and transactions with mergers and acquisitions that matter to you as a practice owner.
Learn more about
Aesthetic BrokersFollow Aesthetic Brokers on Instagram
@aestheticbrokers
